Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sarosy

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Seminars in Oncology|June 1, 1995
Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical resultsE Reed, E C Kohn, G Sarosy, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancerC A Jamis-Dow, R W Klecker, G Sarosy, et al.
Seminars in Oncology|September 1, 1986
Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicinD D Von Hoff, G Sarosy, T D Brown, et al.
Anti-Cancer Drugs|April 1, 1993
The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factorA Bicher, E Kohn, G Sarosy, et al.
Cancer|January 15, 1993
Age does not influence taxol dose intensity in recurrent carcinoma of the ovaryA Bicher, G Sarosy, E Kohn, et al.
Gynecologic Oncology|June 1, 1996
A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovaryE Reed, G Sarosy, E Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancerG Sarosy, E Kohn, D A Stone, et al.
Journal of the National Cancer Institute|January 5, 1994
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancerE C Kohn, G Sarosy, A Bicher, et al.
Selective Cancer Therapeutics|January 1, 1990
Phase I trial and biochemical evaluation of tiazofurin administered on a weekly scheduleT J Melink, G Sarosy, A R Hanauske, et al.
Cancer Research|February 1, 1996
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancersE C Kohn, E Reed, G Sarosy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Seminars in Oncology|June 1, 1995
Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical resultsE Reed, E C Kohn, G Sarosy, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancerC A Jamis-Dow, R W Klecker, G Sarosy, et al.
Seminars in Oncology|September 1, 1986
Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicinD D Von Hoff, G Sarosy, T D Brown, et al.
Anti-Cancer Drugs|April 1, 1993
The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factorA Bicher, E Kohn, G Sarosy, et al.
Cancer|January 15, 1993
Age does not influence taxol dose intensity in recurrent carcinoma of the ovaryA Bicher, G Sarosy, E Kohn, et al.
Gynecologic Oncology|June 1, 1996
A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovaryE Reed, G Sarosy, E Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancerG Sarosy, E Kohn, D A Stone, et al.
Journal of the National Cancer Institute|January 5, 1994
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancerE C Kohn, G Sarosy, A Bicher, et al.
Selective Cancer Therapeutics|January 1, 1990
Phase I trial and biochemical evaluation of tiazofurin administered on a weekly scheduleT J Melink, G Sarosy, A R Hanauske, et al.
Cancer Research|February 1, 1996
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancersE C Kohn, E Reed, G Sarosy, et al.
Pageof 3